Zusammenfassung
HINTERGRUND: Das Magenkarzinom ist in vielen Ländern noch immer die am häufigsten vorkommende Neoplasie. Es werden daher neben den als prognostische Marker bekannten klinisch pathologischen Faktoren, neue – davon unabhängige – Parameter untersucht. Ziel der Studie war die Untersuchung einer Expression des TGF-β1, sowie des TGF-β1-II Rezeptors (TGF-β1-RII) in HER-2-negativen Magenkarzinomen. Weiters wurde untersucht, ob eine Korrelation dieser Parameter mit klinisch-pathologischen Risiko- bzw. Prognosefaktoren des Magenkarzinoms besteht. PATIENTEN UND METHODEN: Gewebeproben von 42 Patienten, die einer kurativen Magen Resektion wegen eines Magenkarzinoms unterzogen worden waren, wurden immunhistochemisch auf das Vorliegen von HER2/neu, TGF-β1 und TGF-β1RII untersucht. Die Expression der Proteine wurde mit klinisch-pathologischen Parametern der Patienten korreliert und auf ihre prognostische Bedeutung ausgewertet. ERGEBNISSE: Alle untersuchten Proben waren HER2/neu negativ. Die Analyse des TGF-β1 ergab eine immunhistochemische Anfärbung vor allem im Zytoplasma und an der Membran. Unsere Ergebnisse zeigten, dass 80 % der intestinalen Magenkarzinom Proben eine TGF-β1 Expression aufwiesen, während das nur bei 43 % der Proben des diffusen Typs der Fall war. Auch die Tumoren mit niedriger oder mäßiger Differenzierung waren in Bezug auf TGF-βRII immunhistochemisch positiv (p = 0,041). Schließlich wurde eine mediane Überlebenszeit von 37,03 Monaten erhoben. Die Patienten mit TGF-β1 Expression hatten im Vergleich zu den Patienten, bei denen keine Expression von TGF-β1 nachgewiesen werden konnte (p = 0,034) eine schlechtere Prognose nach der chirurgischen Therapie. SCHLUSSFOLGERUNGEN: Wir konnten zeigen dass der Nachweis einer TGF-β1 Expression im Gewebe von Magen Tumoren, die einen HER2nez/negativen Status aufweisen, prognostisch ungünstig ist. Die für TGF-β1 and TGF-βRII erhobenen Ergebnisse zeigten eine Korrelation mit klinisch pathologischen Parametern. Der histologische Typ und der Differenzierungsgrad korrelierte mit dem Nachweis von TGF-β1. TGF-β1 positive Patienten hatten eine vergleichsweise kürzere Überlebenszeit als die TGF-β1 negativen Patienten.
Summary
BACKGROUND: Gastric cancer is still the most prevalent neoplasia in many countries. Therefore, besides the clinicopathological factors known to be prognostic markers, new independent parameters are being investigated. This study was to investigate the expression of transforming growth factor – β1 (TGF-β1) and transforming growth factor – β1 receptor II (TGF-β1RII) in HER2/neu negative gastric carcinomas and to explore the correlations, the clinicopathological characteristics and prognosis of gastric carcinoma. PATIENTS AND METHODS: Surgical specimens from 42 patients with gastric cancer were examined for the presence of HER2/neu, TGF-β1 and TGF-β1RII by immunohistochemistry. The correlation between expression of the proteins and patient clinicopathological parameters was evaluated and the prognostic significance of TGF-β1 and of receptor expression was assessed. RESULTS: All specimens demonstrated HER2/neu-negative status. TGF-β1 analyses exhibited predominantly cytoplasmic and membranous immunostaining. We found that 80% of intestinal gastric cancer specimens have TGF-β1 expression, while in the diffuse type they are 43%. Also the tumors with low and moderate differentiation were positive for TGF-βRII (p = 0.041). Finally we found that median survival period of the patients was 37.03 months and the patients with TGF-β1 expression had worse prognosis after surgical therapy compared to those without expression of TGF-β1 (p = 0.034). CONCLUSIONS: We have shown that TGF-β1 expression in gastric tumor tissue with HER2/neu-negative status is of prognostic relevance in gastric cancer. The data for TGF-β1 and TGF-βRII expression showed association with clinicopathological parameters, and more precisely with the differentiation and histology type and TGF-β1-positive patient had a shorter overall survival compared with TGF-β1-negative patients.
References
The Lancet Oncology. New hope for advanced gastric cancer. Lancet Oncol 2010;11(3):211
Farrow D, Vaughan T. Determinants of survival following the diagnosis of esophageal adenocarcinoma. Cancer Causes Control 1996;7(3):322–7
Gravalos G, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19(9):1523–9
Akiyama T, Sudo C, Oogawara H, Toyoshima K, Yyamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644–6
Coussens L, Yyang-Feng TL, Lliao YC. Tyrosine kinase receptor with extensive homology to EGegF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132–9
Lee KE, Lee HJ, Kim YH. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003;33:173–9
Xie SD, Xu CY, Shen JG, et al. HER 2/neu protein expression in gastric canceris associated with poor survival. Molecular Medicine REPORTS 2009;2:943–6
Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137–61
Fujiwara T, Stolker JM, Watanabe T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol 1998;153:1063–78
Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF β pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93–102
Shurin MR, Shurin GV, Lokshin A, et al. Intratumoral cytokines/chemokines/ growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis 2006;25:333–56
Ebert MP, Yu J, Miehlke S, et al. Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucosa of first-degree relatives of patients with gastric cancer. Br J Cancer 2000; 82(11):1795–800
Polyak K. Negative regulation of cell growth by TGF beta. Bichem Biophys Acta 1996; 1242:185–99
Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor β with tumor progression. Cell Growth Differ 1994;5:267–75
Muraoka RS, Koh Y, Roebuck LR, et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 2003;23: 8691–703
Wilson CA, Cajulis EE, Green JL, et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005;7:R1058–79
Sobin LH, Wittekind Ch (Eds.) Wiley-Liss UICC. TNM Classification of Malignant Tumours 6th ed. (2002): New York 2002
Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49
Ross JS, McKenna BJ. The HER-2 / neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19;554–68
Shinohara H, Morita S, Kawai M, et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res 2002;102:169–77
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumorassociated protease systems. J Clin Oncol 2000;18:2201–9
Massagué J. TGFbeta in Cancer. Cell 2008;134(2):215–30
Lu B, Zhou YN, Li Q, Wu ZQ, Zhang ZY, Ji R, et al. Correlations of TGF-betaRII, Smad4 and Smad7 expression to clinicopathologic characteristics and prognosis of gastric cancer. Ai Zheng 2009;28(5):538–42
Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 1999;86:1455–62
Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, et al. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer 2007;97(3):398–404
Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor b1 in patients with colorectal cancer: Association with disease progression. Gastroenterology 1996;110:375–82
Gorsch SM, Memoli VA, Stukel TA, et al. Immunohistochemical staining for transforming growth factor b1 associates with disease progression in human breast cancer. Cancer Res 1992;52:6949–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ananiev, J., Gulubova, M., Tchernev, G. et al. Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. Wien Klin Wochenschr 123, 668–673 (2011). https://doi.org/10.1007/s00508-011-0078-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-011-0078-9